Inspra (Eplerenone)

Eplerenone selectively blocks mineralocorticoid receptors in the kidney’s distal tubules, preventing aldosterone from promoting sodium reabsorption and potassium loss. This leads to increased sodium excretion, reduced fluid volume, lower blood pressure, and decreased cardiac remodeling.

The dosage of Inspra is individualized by the prescribing clinician based on the patient’s condition, kidney function, and serum potassium levels. Patients should follow the dose and titration schedule provided by their healthcare professional.

The safety of eplerenone in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both eplerenone (Inspra) and spironolactone are aldosterone antagonists, but eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer anti‑androgenic side effects such as gynecomastia. Dosing and monitoring principles are similar, though individual patient response may differ.

Inspra tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight to maintain potency throughout the shelf life.

Inspra is taken orally, usually once daily, with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber.

The most serious risks include hyperkalemia (dangerously high potassium levels) and acute kidney injury. Patients should have regular laboratory monitoring of serum potassium and renal function, especially when starting therapy or adjusting the dose.

Inspra should be avoided in patients with known hyperkalemia, severe renal impairment, or those taking other potassium‑sparing agents that could raise potassium levels. It is also contraindicated in individuals with a known hypersensitivity to eplerenone.